NSCLC possess a higher baseline of PD-L1, but a recent finding has shown that NSCLC is resistant to cisplatin and undergoes epithelial–mesenchymal transition to enable invasion/metastasis as well as to escape immune surveillance by expressing even higher PD-L1. Here, CD274 is linked to non-small cell lung carcinoma.